KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Non-Current Deffered Revenue (2019 - 2022)

Esperion Therapeutics' Non-Current Deffered Revenue history spans 3 years, with the latest figure at $211000.0 for Q2 2022.

  • For Q2 2022, Non-Current Deffered Revenue fell 80.04% year-over-year to $211000.0; the TTM value through Jun 2022 reached $211000.0, down 80.04%, while the annual FY2021 figure was $634000.0, N/A changed from the prior year.
  • Non-Current Deffered Revenue reached $211000.0 in Q2 2022 per ESPR's latest filing, down from $422000.0 in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $1.1 million in Q2 2021 to a low of $211000.0 in Q2 2022.
  • Average Non-Current Deffered Revenue over 3 years is $637333.3, with a median of $644500.0 recorded in 2019.
  • The largest YoY upside for Non-Current Deffered Revenue was 80.04% in 2022 against a maximum downside of 80.04% in 2022.
  • A 3-year view of Non-Current Deffered Revenue shows it stood at $655000.0 in 2019, then fell by 3.21% to $634000.0 in 2021, then crashed by 66.72% to $211000.0 in 2022.
  • Per Business Quant, the three most recent readings for ESPR's Non-Current Deffered Revenue are $211000.0 (Q2 2022), $422000.0 (Q1 2022), and $634000.0 (Q4 2021).